Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(5): e10655.
Published online 2010 May 17. doi:  10.1371/journal.pone.0010655
PMCID: PMC2871797

In Vivo, Multimodal Imaging of B Cell Distribution and Response to Antibody Immunotherapy in Mice

Derya Unutmaz, Editor



B cell depletion immunotherapy has been successfully employed to treat non-Hodgkin's lymphoma. In recent years, increasing attention has been directed towards also using B-cell depletion therapy as a treatment option in autoimmune disorders. However, it appears that the further development of these approaches will depend on a methodology to determine the relation of B-cell depletion to clinical response and how individual patients should be dosed. Thus far, patients have generally been followed by quantification of peripheral blood B cells, but it is not apparent that this measurement accurately reflects systemic B cell dynamics.

Methodology/Principal Findings

Cellular imaging of the targeted population in vivo may provide significant insight towards effective therapy and a greater understanding of underlying disease mechanics. Superparamagnetic iron oxide (SPIO) nanoparticles in concert with near infrared (NIR) fluorescent dyes were used to label and track primary C57BL/6 B cells. Following antibody mediated B cell depletion (anti-CD79), NIR-only labeled cells were expeditiously cleared from the circulation and spleen. Interestingly, B cells labeled with both SPIO and NIR were not depleted in the spleen.


Whole body fluorescent tracking of B cells enabled noninvasive, longitudinal imaging of both the distribution and subsequent depletion of B lymphocytes in the spleen. Quantification of depletion revealed a greater than 40% decrease in splenic fluorescent signal-to-background ratio in antibody treated versus control mice. These data suggest that in vivo imaging can be used to follow B cell dynamics, but that the labeling method will need to be carefully chosen. SPIO labeling for tracking purposes, generally thought to be benign, appears to interfere with B cell functions and requires further examination.


Immunotherapeutic depletion of B cells is a clinically approved approach for the treatment of non-Hodgkin's lymphoma, a type of cancer derived from lymphocytes [1]. Rituximab, an engineered anti-CD20 monoclonal antibody that targets B cells at most stages of development, functions therapeutically by specifically eradicating CD20-positive lymphocytes from the patient [2]. Its success has led to its application against a range of non-malignant B cell pathogenic diseases. These include IgM-associated polyneuropathy [3], [4], [5], multiple sclerosis [6], dermatomyositis [7], rheumatoid arthritis (RA) [8], [9], relapsing-remitting multiple sclerosis, and systemic lupus erythematosus (SLE) [10], [11], [12]. Controlled studies with rituximab have already demonstrated a reduction of disease activity in RA patients [13], [14], [15], resulting in its clinical approval for treatment of this autoimmune disease. However, rituximab has failed to show clinical efficacy in Phase II and III trials for treatment of primary progressive multiple sclerosis [16] and SLE [17], [18], [19], [20].

In the clinical setting, the effectiveness of depletion is usually followed through quantification of peripheral blood B cells. However, in SLE patients this measure varies widely for a given dose [21], [22], and does not seem to adequately reflect patient response [10], [12]. Appreciation of the biological response to treatment within the lymphoid organs is therefore expected to be beneficial for greater understanding of underlying disease mechanisms and insight towards development of effective therapies [23].

Cellular and molecular imaging techniques can be used non-invasively, quantitatively and repetitively to visualize cell populations in vivo [24]. Previous studies have utilized radioactive [25], fluorescent [26], [27] and bioluminescent imaging (BLI) [28], [29] approaches to investigate lymphocyte distribution. Recently, a BLI transgenic model was used to monitor the effect of rituximab depletion of a transgenic lymphoma model [30]. Cellular imaging may provide a means to assess the biological response to anti-CD20 and other immunotherapeutics, thereby providing insight into the dose-response behavior and efficacy of treatment.

Magnetic resonance (MR) is a powerful diagnostic tool in preclinical and clinical use that provides high resolution and deep tissue anatomical information. Cell tracking via MR imaging has been realized using superparamagnetic iron oxide (SPIO) nanoparticle contrast agents in a variety of cell types and animal disease models [31], [32], [33]. In the present work we have implemented an ex vivo labeling strategy to load B cells with a non-toxic SPIO configuration, previously determined to efficiently label lymphocytes [34], in combination with a non-toxic near infrared (NIR) cell membrane labeling dye [35]. This approach enabled us to utilize, longitudinally, both MR and optical methods to track contrast labeled cells in the spleen, prior to and following administration of B cell depleting antibody.


Labeling of primary murine B cells

The loading of B cells harvested from the spleens of C57BL/6 mice was performed using a cationic 53.5 nm diameter SPIO nanoparticle, schematically illustrated in Figure 1A, through a previously validated procedure [34]. Cells were also labeled with a lipophilic membrane associating dye, CellVue NIR 815 (NIR815), to enable deep tissue fluorescent imaging (Fig. 1B). The proficient loading of the cells was confirmed by fluorescent microscopy, Fig. 1C. B cells from GFP-transgenic mice were employed in order to identify injected cells histologically upon conclusion of in vivo imaging.

Figure 1
Labeling of B cells with fluorescent and MR tracers and evaluation of cellular response.

Prior to animal experimentation, the expression levels of several cell surface markers were assessed to determine whether SPIO and NIR815-loading led to any change in the cell-activation state. Specifically, the expression levels of CD40, CD80, CD86 and MHC II were evaluated in unlabeled, SPIO-loaded and PMA-activated B cells via flow cytometry, Fig. 1D. No significant change in surface expression was observed between SPIO-labeled and unlabeled cells. PMA, which is known to cause B cell activation [36], resulted in the upregulation of CD40, CD86, and CD80 and the downregulation of MHC II.

The ability of B cells to become activated 24 h after labeling with SPIO was also assessed by monitoring whether treatment with LPS led to cell surface expression patterns that mirrored cells treated with LPS alone. It was found that LPS mediated a similar increase in the expression of CD40, CD80, CD86 and MHC II for both SPIO-labeled and unlabeled B cells (Fig. 1E). These findings suggest that SPIO-loading does not interfere with normal B cell function. Therefore, NIR815-labeled B cells with and without SPIO were administered to C57BL/6 mice and imaged longitudinally to observe the distribution of the B cell population (Table 1).

Table 1
Study Groups; Contrast and Treatment.

The experimental timeline is illustrated in Fig. 1F. The specific days in which MR and optical imaging were performed are indicated. Animals were treated either with PBS or anti-CD79 antibodies one day following the administration of B cells (immediately after imaging) to determine whether B cell depletion could be directly monitored within the spleen. In addition, one animal from each group (Table 1) was sacrificed and the organs excised for additional analysis.

Small animal magnetic resonance imaging of cell trafficking

MR imaging was used longitudinally to monitor the trafficking and biodistribution of B cells labeled with both SPIO and NIR815 or NIR815 only (i.e. SPIO-free). One day following the administration of SPIO-labeled B cells, the spleen appeared darker on T2*-weighted images (Fig. 2A, row i). This hypointensity is consistent with the accumulation of SPIO. The spleen remained hypointense for several days, but gradually returned to near baseline over the course of two weeks. Animals that were treated with anti-CD79 antibody one day following the administration of SPIO-labeled B cells (Fig. 2A, row ii) exhibited a similar pattern of contrast enhancement as the control (PBS-treated) animals over the course of the study.

Figure 2
Longitudinal MR imaging and quantification of contrast-labeled B cells prior to and following B cell depletion therapy.

There was no apparent signal change in the spleen one day after animals were injected with B cells labeled with just NIR815 dyes (Fig. 2A, row iii). However, animals that were subsequently treated with anti-CD79 antibodies did exhibit a gradual loss in T2*-weighted signal within the spleen over the following two weeks (Fig. 2A, row iv). No change in T2*-weighted signal was observed in PBS-treated controls over the same time period.

Quantitative measurements of lymphocyte homing to the spleen were determined by measuring the signal intensity within the spleen. All measurements were normalized by the signal intensity of the surrounding muscle to adjust for image variability. The resulting value is referred to as the relative signal intensity (rSI). All rSI values were further normalized by day 0 measurements. The normalized rSI was reduced ~40% one day following injection of SPIO-loaded B cells, compared with pre-contrast images (Fig. 2B, groups i and ii). Over the following two weeks, the normalized signal ratio gradually increased towards pre-contrast values. There was no statistically significant difference (p<0.05) in normalized rSI between untreated (i) and treated (ii) groups. These findings suggest that SPIO could potentially interfere with the efficacy of B cell depletion therapy. Animals that had SPIO-free B cells (i.e. NIR815 only) administered exhibited a statistically significant difference in the normalized rSI between treated and untreated groups (Fig. 2B, iii and iv) at day 7. There also appeared to be some difference on day 14, but variability of rSI was too great to achieve statistical significance at this time point.

To confirm that B cells were actually being depleted following the administration of anti-CD79 antibody, peripheral B cell counts were acquired from sacrificed animals at each imaging time point. It was found that the B cells were in fact rapidly depleted, reaching a minimum approximately 4 days after the injection of anti-CD79 antibodies (Fig. 2C). Thereafter, the number of peripheral B cells gradually increased, returning to baseline levels approximately 9-14 days after treatment.

Whole body in vivo fluorescent imaging

In addition to MR imaging, it was possible to detect and monitor the trafficking and distribution of the introduced B cell population via NIR fluorescence imaging (Fig. 3A). Acquisitions of both Alexa 680 (i.e. fluorescent label on SPIO) and CellVue NIR815 (membrane dye) were obtained; however, there was insufficient signal from the Alexa 680 dye to be detected above the autofluorescence of living animals (not shown).

Figure 3
In vivo fluorescent imaging of contrast-labeled B cells prior to and following B cell depletion therapy.

Whole body in vivo fluorescent imaging showed that the B cells in all test groups were predominantly localized within the spleen one day after delivery (Fig. 3A). Little fluorescence was seen outside the spleen, except at the site of tail vein injection where presumably a small percentage of cells had leaked subcutaneously. Consistent with MR imaging data, B cells that were labeled with SPIO and NIR815 did not appear depleted following administration of anti-CD79 antibodies (Fig. 3A, row i), compared with PBS treated controls (Fig. 3A, row ii). In both groups, the fluorescent signal within the spleen decreased gradually over the course of the experiment returning to near baseline levels by day 15. In contrast, the rapid depletion of B cells labeled with only NIR815 (i.e. SPIO-free) could be observed via fluorescence imaging (Fig. 3A, rows iii and iv). Within two days of administration of anti-CD79 antibody, the fluorescent signal was reduced to near baseline levels, whereas B cells within PBS-treated control animals exhibited a detectable, although decreasing, fluorescent signal as late as 14 days after the administration of PBS.

The effect of the B cell depleting antibody was quantified through measurement of fluorescent intensity in the spleen relative to the background (SBR), Fig. 3B. These data revealed that when cells were labeled with SPIO and NIR815, there was no statistical difference in the SBR between anti-CD79 antibody- and PBS-treated subjects (Fig. 3B). Conversely, when cells were labeled with NIR815 alone, there was a ~65% reduction in the SBR two days following the administration of anti-CD79 antibodies compared with only a 20% reduction of SBR in PBS-treated controls (Fig. 3C). The difference in the SBR between treated and untreated groups remained statistically significant for the remainder of the study, 14 days in total.

Ex vivo organ fluorescence

Fluorescent images of the excised liver, lungs, heart and spleen were acquired from a single animal from each group, at each time point (Fig. 4A). The distribution of B cells as determined by ex vivo fluorescence imaging confirmed that homing to the spleen was rapid. One day after B cell injection a strong signal was observed in the spleen. Significantly less fluorescence was observed in the liver and little to no signal was detectable in the heart or lungs. Consistent with live animals imaging studies, SPIO seemed to interfere with the ability to deplete the transferred cells as there was no significant difference between control and treated mice (Fig. 4B). However, in the absence of SPIO, B cell depletion could be readily observed through the loss of NIR815 fluorescence in the spleen. Quantitative analysis revealed a ~80% reduction in the mean fluorescence intensity (MFI) of NIR815 within the spleen only two days after the administration of anti-CD79 antibodies (Fig. 4C). Mice treated with PBS only exhibited a ~35% reduction in MFI at the same time point.

Figure 4
Fluorescent images of contrast-labeled B cells in excised organs.


Immediately following ex vivo fluorescent imaging of the excised organs, the spleens were sectioned and imaged by fluorescence microscopy (Fig. 5). In animals that had been injected with SPIO-labeled B cells, there was a clear co-localization between the GFP-positive B cells, Alexa-680 (i.e. fluorescent label on SPIO), and NIR815. In contrast, in animals where no B cells were administered, only low levels of autofluorescence were apparent. These results provide strong evidence that the SPIO and NIR815 signals reflect the actual B cell biodistribution, i.e. the contrast agents are not transferred to other cells over the course of the experiment.

Figure 5
Fluorescent images of spleens following histological sectioning.


There currently exists both an academic and clinical deficit in the techniques available to monitor B cell depletion quantitatively within organs. This manifests as a significant problem considering the high degree of variability in the response of patients to rituximab treatment [37], [38], [39], [40]. Critically, this also hinders development of novel therapeutics for B cell dysfunction-dependent diseases resistant to anti-CD20 treatment, such as SLE [23]. The evaluation of treatment efficacy and correlation to clinical outcome can only be determined under fixed time-point, ex vivo methodologies or through peripheral blood B cell measurements of limited value. Several bioluminescent imaging approaches to visualize treatment of B cell lymphoma have been described; however these non-translatable strategies have utilized chimeric mouse models to enable the evaluation of human antibody targeting [30]. In the present study we have evaluated the ability of SPIO and NIR815 membrane dyes to enable in vivo observation of B cell distribution and response to antibody mediated depletion using MR and fluorescent imaging.

Cationic SPIO were efficiently internalized by isolated primary B cells during a simple 2 h incubation period. Internalization did not significantly alter morphology, lead to clumping, or affect the surface expression patterns of isolated B cells as assessed by the measurement of CD40, CD80, CD86 and MHC II expression by immunostaining and flow cytometry. Further, SPIO did not appear to interfere with the ability of isolated B cells to become activated upon treatment with LPS. These findings led us to initially believe that SPIO were essentially intracellularly inert after loading, with no detectable impact on the functionality of B cells.

Following the transfer of SPIO-labeled B cells into C57BL/6 mice, a dramatic reduction in MR signal intensity was observed within the spleen on T2*-weighted images, consistent with the accumulation of iron oxide nanoparticles. Homing to the spleen was also observed through fluorescence imaging of NIR815 in both live animals and excised organs. However, administration of anti-CD79 antibodies did not result in any significant splenic depletion of the SPIO-labeled B cells in recipient C57BL/6 mice compared with PBS-treated control animals. This was verified through MR imaging as well as optical imaging of live animals and excised organs.

To ensure that the administered anti-CD79 antibodies were capable of effectively depleting B cells, peripheral B cell counts were acquired over the course of the study. As expected, the endogenous B cells were rapidly depleted from circulation. It should be noted that the depletion of peripheral B cells has previously been shown to correlate with the depletion of B cells within the spleen of healthy animals [41], [42]. These findings suggest, in contradistinction to the in vitro B cell functionality and expression assays and the apparently normal B cell trafficking to the spleen, that SPIO-labeling does interfere with B cell regulation in vivo. The interference was SPIO-specific as B cells that were subject to isolation and labeling with just the membrane dye could be depleted with anti-CD79 antibodies following their transfer into C57BL/6 mice. The same protocol was followed in both studies, outside of the additional 2 h incubation with SPIO. Therefore, SPIO seem to have subtle effects on B cell function that could easily be overlooked. This is a particularly important finding when considering the use of SPIO for cell tracking applications. Numerous, pre-clinical studies have already been conducted illustrating the ability to monitor cell distribution via MR, including applications involving dendritic cells, T-lymphocytes, natural killer (NK) cells, macrophages and stem cells [43], [44], [45], [46], [47]. However, very few of these studies look at downstream functionality beyond cell homing. Our findings suggest that cell trafficking alone may not be a sufficient marker for normal cell behavior and that caution must be taken when applying these methods.

Recently, several studies have also found that adverse cellular effects may result from iron oxide particle labeling [48], or that SPIO may not be suitable for long term in vivo visualization [49]. The current system in which both a fluorescent cell associated dye and SPIO have been used has the potential to provide insight into the interfering effects of nanoparticulate contrast media.

Despite the shortcomings of SPIO-labeling in this study, B cells that were subject to labeling with just the NIR815 membrane dye could be effectively depleted with anti-CD79 antibody following transfer into C57BL/6 mice. The whole body fluorescent tracking of this population of B cells enabled direct, longitudinal and quantitative examination of both the initial accumulation and subsequent depletion of the B lymphocytes in the spleen. We believe that this imaging approach can be extended to animal models of autoimmune disease and will allow greater understand of the efficacy and physiological impact of various depletion therapies.

Materials and Methods

All chemicals and equipment were purchased from Fisher Scientific (Pittsburgh, PA), unless otherwise noted. Mice (Jackson Laboratories; Bar Harbor, ME) were housed under USDA- and AAALAC-approved conditions with free access to food and water. The University of Pennsylvania Institutional Animal Care and Use Committee and Small Animal Imaging Facility (SAIF) Animal Oversight Committee approved all experimental procedures. All in vivo imaging was conducted at the SAIF in the Department of Radiology at the University of Pennsylvania.

Nanoparticle Synthesis and Modification

SPIO, 53.5 nm hydrodynamic diameter, R2 of 82 mM−1sec−1, were produced as previously described [34]. Briefly, iron chloride salts (4 g of FeCl3 and 1.5 g of FeCl2) were chemically co-precipitated through base addition in inert atmosphere at 4°C in the presence of dextran-T10 (25 g, GE Healthcare; Waukesha, WI). The solution was heated to 90°C for 1 h and then ultracentrifuged at 20 k RCF. SPIO were purified from reactants via diafiltration (100 kDa MWCO; GE Healthcare) against 0.02 M citrate buffer.

The dextran coating was cross-linked in base (25% v/v 10 M NaOH) with epichlorohydrin (33%) for 24 h. Subsequently, the dextran was aminated by adding NH4OH to a volume fraction of 25%. The reaction was allowed to proceed for another 24 h. Again, particles were diafiltrated from excess reactants. The resulting particles were reacted at a 1[ratio]10 molar ratio of SPIO:Alexa Fluor 680 (Invitrogen; Carlsbad, CA) in pH 9 sodium bicarbonate buffer. The labeled particles were purified on a PD10 gel filtration column in PBS to yield approximately 3 dye molecules per particle.

Cell Labeling

Splenocytes were obtained from C57BL/6 or C57BL/6-Tg(UBC-GFP)30Scha/J mice, as required. B cells were purified using red blood cell lysing buffer and anti-CD43 MACS beads (Miltenyi Biotec; Hamburg, Germany) for negative selection [50]. B cells were incubated with nanoparticles (50 µg/mL) in fully supplemented RPMI 1640 (ATCC; Manassas, VA) for 2 h. The cells were washed of non-internalized SPIO and labeled with a 1/50 dilution of CellVue® NIR815 dye (NIR815, Molecular Targeting Technologies; Malvern, PA) following manufacturer instructions. For NIR815-only labeled cells, the SPIO labeling step was omitted.

Animal Procedures

Four groups of 8 adult (8 week old) male C57BL/6 mice were placed on AIN-76A low-autofluorescence rodent diet (Research Diets, Inc.; New Brunswick, NJ). Six days after food change, animals were tail vein injected with 20 M primary B cells derived from GFP-transgenic mice. Two groups were injected with SPIO and NIR815-labeled cells, and two with cells that were labeled with the NIR815 dye alone; Table 1. Three subjects per group were imaged using MR and whole-body fluorescent imaging at each of the following time points; prior to administration, 1, 3, 5, 7, 10 and 15 days post-injection.

Immediately following the day 1 imaging time point, an intraperitoneal injection (IP) of either 200 µg of anti-CD79β (MH79-16, Armenian hamster IgG [42], [51]) or PBS was given. Peripheral blood lymphocytes (PBL) were measured, and the heart, liver, lungs and spleen were removed for ex vivo fluorescent organ imaging (Odyssey, LiCOR; Lincoln, NE) from one mouse per group at each time point. PBL were purified of red blood cells with ACK and stained with anti-CD19-FITC (1d3, rIgG). The cells were subsequently fixed with 4% formaldehyde and PBL counts were measured by flow cytometry (Easycyte, Guava Technologies, Inc; Hayward, CA).

Cell Activation

Activation of primary C57BL/6 B cells or splenocytes by incubation with SPIO, phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich; St. Louis, MO) and lipopolysaccharide (LPS - E. Coli 055:B5, Sigma) was assessed by flow cytometry. B cells were incubated with SPIO (as above), washed and maintained in culture media for 24 h. As a positive control for activation, unlabeled B cells were incubated with LPS (0.01 µg/mL) for 24 h. B cells were also assessed for their ability to activate after loading with SPIO by adding LPS to the culturing medium of SPIO-labeled cells and incubating for 24 h. Activation was measured by changes in surface marker expression: antibodies (1/200) against CD40 (PE), CD86 (PE), CD80 (FITC) and MHCII (FITC) were used to label cells after triplicate washing from culture media into 0.1% BSA in PBS. To prevent internalization of antibody, labeling was conducted on ice.

In Vivo Fluorescence Imaging

Mice were induced with inhalation anesthesia, using in a 4% mixture of Isoflurane in oxygen. Mice were maintained at a 2% mixture of the gas and shaved on their left side. 2-2-2 Tribromoethanol (Avertin; 500 mg/kg dose; approximately 200 µL) was administered IP 10 minutes before imaging to keep animals motionless during acquisition. Spectral fluorescence images of recumbent mice were acquired using a Maestro fluorescence imaging system (CRi; Woburn, MA). The red filter set (excitation range 615 to 665 nm; emission, 700 nm longpass) was used to detect Alexa680-SPIO and the near infrared filter set (excitation range 710 to 760 nm; emission, 800 nm longpass) enabled detection of the cell membrane bound NIR815. Each spectral image set was acquired using a 5 sec exposure with acquisition at 10 nm steps through the emission range. The spectral fluorescence images consisted of data from the two dyes. The autofluorescence spectra were then unmixed based on their spectral patterns using commercial software (Maestro software, CRi). Line intensities were generated through the long axis of the spleen. Mean intensities of the signal at this organ and background were computed and averaged for each image.

In Vivo MR Imaging and Analysis

Magnetic resonance imaging was conducted using a horizontal Varian 9.4 T small animal imaging system (Varian; Palo Alto, CA). Gradient coils were upgraded during the course of the study, going from a diameter of 14 to 12 cm and a gradient strength of 10 G/cm to 25 G/cm (both Varian). A dual coil, actively detuned system was employed; a 70 mm receiver volume coil was paired with a 2.5 cm surface coil (InsightMRI, LLC; Worcester, MA). Mice were induced using inhalation anesthesia, 4% isoflurane, and maintained for the duration of image acquisition with 2% isoflurane. The animals were placed on their right side in a split top mouse chamber sled (m2m Imaging; Cleveland, OH) affixed to a custom built poly-(methyl methacrylate) patient bed. The surface coil was applied to the left side of the animal (proximal to the spleen) and fixed in position using surgical tape to both the mouse and bed. Temperature and electrocardiography probes were used to monitor the mice in the 37°C environment supplied by an air heating system (SA Instruments, Inc.; Stony Brook, NY).

Scout scans were used to identify the anatomy of interest. Following recognition of the spleen, axial sections (1 mm thick) were acquired in a 36×36 mm field of view. Acquisition sets consisted of np = 256, nv = 256, under T2*-weighted parameters. A gradient echo multislice sequence was used with 2 averages, and TR/TE 200/6 msec. Images were analyzed by defining a ROI for the spleen and background (paraspinal) muscle. The relative intensity of the spleen was then calculated, and statistical significance for the image analysis was assessed using a two-tailed parametric analysis. A p-value<0.05 was used to represent statistical significance.

Fluorescence Microscopy

Fluorescence microscopy was performed using an Olympus IX 81 motorized inverted fluorescence microscope equipped with an Ixon (Andor Technologies; Belfast, N. Ireland) monochrome digital camera, an X-Cite 120 excitation source (EXFO; Quebec, PQ) and Sutter excitation and emission filter wheels (Novato, CA). Images were acquired using a LUC PLAN FLN 40× objective (NA 0.6) with Alexa 680 and NIR815 filter sets, (HQ665/45, Q695LP, HQ725/50) and (HQ710/75, Q750LP, HQ810/90), respectively (Chroma Technology Corp.; Burlington, VT).


Immediately following ex vivo fluorescent imaging of the excised organs, spleens were embedded in Optimal Cutting Temperature compound (Tissue-Tek, Sakura Finetek Americas, Inc.; Torrance, CA). Fresh cut sections (8 µm thickness) were air dried for 1 hr and then sealed under coverslips with cyanoacrylate ester glue. Tissue was imaged for GFP (HQ480/40×, Q505LP, HQ535/50 m), Alexa 680 and NIR815 by fluorescence microscopy, as above.


All data are presented as mean ± standard error. For statistical evaluation, a two-tailed Student's t-test was used, and p<0.05 was considered significant. Calculations were performed using a commercially available plotting and statistics software package (GraphPad Prism; GraphPad Software, San Diego, CA).


The authors thank Dr. Yvette Liu, Dr. Steven Pickup and Dr. Weixia Liu at the SAIF for their imaging expertise. We would also like to thank Michael Smith (Wyeth) for his helpful suggestions and insightful comments.


Competing Interests: This work was supported in part by Wyeth-Ayerst Pharmaceuticals. However, all information and materials are freely available in adherence with PLoS ONE policies on sharing data and materials.

Funding: This work was supported in part by Wyeth-Ayerst Pharmaceuticals, the Transdisciplinary Program in Translational Medicine and Therapeutics, Department of Defense Office of the Congressionally Directed Medical Research Program (W81XWH-07-1-0457) and the Lupus Research Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Grillo-Lopez AJ, White CA, Dallaire BK, Varns CL, Shen CD, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1:1–9. [PubMed]
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445. [PubMed]
3. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology. 1999;52:1701–1704. [PubMed]
4. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485–489. [PMC free article] [PubMed]
5. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve. 2003;27:611–615. [PubMed]
6. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688. [PubMed]
7. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601–607. [PubMed]
8. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002;46:2029–2033. [PubMed]
9. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883–888. [PMC free article] [PubMed]
10. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–2589. [PubMed]
11. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673–2677. [PubMed]
12. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580–3590. [PubMed]
13. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806. [PubMed]
14. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N Engl J Med. 2004;350:2572–2581. [PubMed]
15. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390–1400. [PubMed]
16. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology. 2009;66:460–471. [PubMed]
17. Merrill J, Neuwelt C, Wallace D, Shanahan J, Latina sK, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the Randomized, Double-blind Phase II/III Study EXPLORER; 2008; Abstract L12.
18. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–2131. [PubMed]
19. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971–980. [PubMed]
20. Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets. 2006;6:345–350. [PubMed]
21. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724–1731. [PubMed]
22. Sutter JA, Kwan-Morley J, Dunham J, Du Y-Z, Kamoun M, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery. Clinical Immunology. 2008;126:282–290. [PubMed]
23. Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun. 2009;32:223–230. [PMC free article] [PubMed]
24. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science. 2003;302:605–608. [PubMed]
25. Melder RJ, Elmaleh D, Brownell AL, Brownell GL, Jain RK. A method for labeling cells for positron emission tomography (PET) studies. Journal of Immunological Methods. 1994;175:79–87. [PubMed]
26. Fu G, Gascoigne NR. Multiplexed labeling of samples with cell tracking dyes facilitates rapid and accurate internally controlled calcium flux measurement by flow cytometry. J Immunol Methods. 2009;350:194–199. [PMC free article] [PubMed]
27. Parish CR. Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol. 1999;77:499–508. [PubMed]
28. Millington O, Zinselmeyer B, Brewer J, Garside P, Rush C. Lymphocyte tracking and interactions in secondary lymphoid organs. Inflammation Research. 2007;56:391–401. [PubMed]
29. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. Nat Med. 1998;4:245–247. [PubMed]
30. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113:3765–3772. [PubMed]
31. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34:23–38. [PubMed]
32. Bulte JW, Kostura L, Mackay A, Karmarkar PV, Izbudak I, et al. Feridex-labeled mesenchymal stem cells: cellular differentiation and MR assessment in a canine myocardial infarction model. Acad Radiol. 2005;12(Suppl 1):S2–6. [PubMed]
33. Bulte JW. In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol. 2009;193:314–325. [PMC free article] [PubMed]
34. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2008;29:3583–3590. [PMC free article] [PubMed]
35. Tario JD, Gray BD, Wallace SS, Muirhead KA, Ohlsson-Wilhelm BM, et al. Novel Lipophilic Tracking Dyes for Monitoring Cell Proliferation. Immunological Investigations. 2007;36:861–885. [PubMed]
36. Li YY, Yang Y, Bao M, Edwards CK, 3rd, Parnes JR. Mouse splenic B lymphocyte activation using different activation stimuli induces in vitro splicing of tumor necrosis factor-alpha nuclear pre-mRNA. Mol Immunol. 2006;43:613–622. [PubMed]
37. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, et al. Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders. J Clin Oncol. 2005;23:1096–1102. [PubMed]
38. Hainsworth JD, Burris HA, III, Morrissey LH, Litchy S, Scullin DC, Jr, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000;95:3052–3056. [PubMed]
39. McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833. [PubMed]
40. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, et al. Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103–1108. [PubMed]
41. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, et al. Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy. J Immunol. 2005;174:817–826. [PubMed]
42. Li Y, Chen F, Putt M, Koo YK, Madaio M, et al. B Cell Depletion with Anti-CD79 mAbs Ameliorates Autoimmune Disease in MRL/lpr Mice. J Immunol. 2008;181:2961–2972. [PMC free article] [PubMed]
43. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005;15:4–13. [PubMed]
44. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23:1407–1413. [PubMed]
45. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000;18:410–414. [PubMed]
46. Reichardt W, Durr C, von Elverfeldt D, Juttner E, Gerlach UV, et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol. 2008;181:4770–4779. [PMC free article] [PubMed]
47. Valable S, Barbier EL, Bernaudin M, Roussel S, Segebarth C, et al. In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. Neuroimage. 2007;37(Suppl 1):S47–58. [PubMed]
48. Bulte JW, Kraitchman DL, Mackay AM, Pittenger MF. Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood. 2004;104:3410–3412. author reply 3412-3413. [PubMed]
49. Chen I, Greve J, Gheysens O, Willmann J, Rodriguez-Porcel M, et al. Comparison of Optical Bioluminescence Reporter Gene and Superparamagnetic Iron Oxide MR Contrast Agent as Cell Markers for Noninvasive Imaging of Cardiac Cell Transplantation. Molecular Imaging and Biology. 2009;11:178–187. [PubMed]
50. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 1990;11:231–238. [PubMed]
51. Koyama M, Ishihara K, Karasuyama H, Cordell J, Iwamoto A, et al. CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol. 1997;9:1767–1772. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science